Platelet activation in acute myocardial infarction and the rationale for combination therapy
- PMID: 10980904
- DOI: 10.1007/s11886-000-0050-1
Platelet activation in acute myocardial infarction and the rationale for combination therapy
Abstract
Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.
Similar articles
-
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.J Invasive Cardiol. 2000 Dec;12 Suppl E:E5-9;discussion E25-8. J Invasive Cardiol. 2000. PMID: 11156722 Clinical Trial.
-
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.Circulation. 2004 Feb 24;109(7):874-80. doi: 10.1161/01.CIR.0000112604.74713.35. Epub 2004 Feb 2. Circulation. 2004. PMID: 14757697
-
Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.J Am Coll Cardiol. 1999 Nov 1;34(5):1395-402. doi: 10.1016/s0735-1097(99)00364-2. J Am Coll Cardiol. 1999. PMID: 10551684 Review.
-
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.J Am Coll Cardiol. 1999 Mar;33(3):634-9. doi: 10.1016/s0735-1097(98)00635-4. J Am Coll Cardiol. 1999. PMID: 10080462 Clinical Trial.
-
GUSTO IV: expanding therapeutic options in acute coronary syndromes.Am Heart J. 2000 Dec;140(6 Suppl):S103-14. doi: 10.1067/mhj.2000.111606. Am Heart J. 2000. PMID: 11100004 Review. No abstract available.
Cited by
-
Nitric oxide, platelet function, myocardial infarction and reperfusion therapies.Heart Fail Rev. 2003 Jan;8(1):47-54. doi: 10.1023/a:1022194921040. Heart Fail Rev. 2003. PMID: 12652159 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Medical